References
  1. Talotta R, Atzeni F, Bazzichi L, Giacomelli C, Di Franco M, Salaffi F, Sarzi-Puttini P. Algo-dysfunctional syndromes: a critical digest of the recent literature. Clin Exp Rheumatol. 2015;33(1Suppl88): S102-8
  2. Chen X, You J, Ma H, Zhou M, Huang C. Efficacy and safety of hyperbaric oxygen therapy for fibromyalgia: a systematic review and meta-analysis. BMJ Open. 2023 Jan 23;13(1): e062322.
  3. Hampson NB, Ed.: Hyperbaric oxygen therapy: 1999 Committee report. Kensington MD, Undersea and Hyperbaric Medical Society, 1999.
  4. Hadanny A, Efrati S. Oxygen-a limiting factor for brain recovery. Critical Care 2015; 19:307
  5. Wolfe F, Clauw D J, Fitzcharles M A, Goldenberg D L, Häuser W, Katz R L, Mease P J, Russell A S, Russell I J, Walitt B. 2016 Revisions to the 2010/2011 fibromyalgia diagnostic criteria. Seminars in Arthritis and Rheumatism 46 (2016) 319–329
  6. Alciati A, Nucera V, Masala IF, Giallanza M, La Corte L, Giorgi V, Sarzi-Puttini P, Atzeni F. One year in review 2021: fibromyalgia. Clin Exp Reumathol. 2021;39 Suppl 130:3–12.
  7. Siracusa R, Di Paola R, Cuzzocrea S, Impellizzeri D. Fibromyalgia: Pathogenesis, Mechanisms, Diagnosis and Treatment Options Update. Int J Mol Sci. 2021 Apr 9;22(8):3891.
  8. Wolfe, F.; Ross, K.; Anderson, J.; Russell, I.J.; Hebert, L. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum. 1995, 38, 19–28.
  9. Calandre EP, Navajas-Rojas MA, Ballesteros J, GarciaCarrillo J, Garcia-Leiva JM, Rico-Villademoros F: Suicidal ideation in patients with fibromyalgia: A cross-sectional study. Pain Pract 15:168-174, 2015
  10. Fassbender HG, Wegner K: Morphologie und Pathogenese des Weichteilrheumatismus. [Morphology and pathogenesis of soft-tissue rheumatism]. Z Rheumaforsch 1973; 32: 355 – 374
  11. Katz DL, Greene L, Ali A, Faridi Z. The pain of fibromyalgia syndrome is due to muscle hypoperfusion induced by regional vasomotor dysregulation. Med Hypotheses 2007;69(3):517–25.
  12. Casale R, Sarzi-Puttini P, Botto R, Alciati A, Batticciotto A, Marotto D, Torta R. Fibromyalgia and the concept of resilience Clin Exp Rheumatol 2019; 37 (Suppl. 116): S105-13.
  13. Meeus M, Nijs J: Central sensitization: A biopsychosocial explanation for chronic widespread pain in patients with fibromyalgia and chronic fatigue syndrome. Clin Rheumatol 26:465-473, 2007
  14. Theoharides T C, Tsilioni I, Bawazeer M. Mast cells, neuroinfammation and pain in fbromyalgia syndrome. Front Cell Neurosci 2019; 13: 353
  15. Clos-Garcia M, Andrés-Marin N, Fernández-Eulate G, Abecia L, Lavín J L, van Liempd S, Cabrera D, Félix Royo 8, Alejandro Valero 9, Nerea Errazquin 10, María Cristina Gómez Vega 11, Leila Govillard 12, Michael R Tackett 13, Genesis Tejada 14, Esperanza Gónzalez 15, Juan Anguita 16, Luis Bujanda 17, Ana María Callejo Orcasitas 18, Ana M Aransay 19, Olga Maíz 20, Adolfo López de Munain 21, Juan Manuel Falcón-Pérez 22 Gut microbiome and serum metabolome analyses identify molecular biomarkers and altered glutamate metabolism in fbromyalgia. EBioMedicine 2019; 46: 499-511.
  16. Harris R E, Sundgren P C, Craig A D, Kirshenbaum E, Sen A, Napadow V, et al. Elevated insular glutamate in fibromyalgia is associated with experimental pain. Arthritis Rheum. 2009;60(10):3146-52
  17. Foester B R, Petrou M, Edden R A, Sundgren P C, Schmidt-Wilcke T, Lowe S E et al. Reduced insular gamma-aminobutyric acid in fibromyalgia. Arthritis Rheum 2012;64(2):579-83.
  18. P. B. Wood, P. Schweinhardt, E. Jaeger et al., “Fibromyalgia patients show an abnormal dopamine response to pain,” The European Journal of Neuroscience, vol. 25, no. 12, pp. 3576– 3582, 2007
  19. P. Sarchielli, M. Di Filippo, K. Nardi, and P. Calabresi, “Sensitization, glutamate, and the link between migraine and fibromyalgia,” Current Pain and Headache Reports, vol. 11, no. 5, pp. 343–351, 2007.
  20. I. J. Russell, M. D. Orr, B. Littman et al., “Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome,” Arthritis and Rheumatism, vol. 37, no. 11, pp. 1593–1601, 1994.
  21. Choy E, Perrot S, Leon T, Kaplan J, Petersel D, Ginovker A, Kramer E: A patient survey of the impact of fibromyalgia and the journey to diagnosis. BMC Health Serv Res 10:102, 2010
  22. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, Tugwell P, Campbell SM, Abeles M, Clark P: The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 33:160-172, 1990
  23. Hauser W, Sarzi-Puttini P, Fitzcharles M-A: Fibromyalgia syndrome: under-, over-and misdiagnosis. Clin Exp Rheumatol 2019; 37 (Suppl. 119): S90-7.
  24. Undersea and Hyperbaric Medical Society. Indications for hyperbaric oxygen therapy. https://www.uhms.org/resources/ hbo-indications.html.
  25. Yildiz S, Kiralp MZ, Akin A, Keskin I, Ay H, Dursun H, Cimsit M. A new treatment modality for fibromyalgia syndrome: hyperbaric oxygen therapy. J Int Med Res. 2004 May-Jun;32(3):263-7.
  26. A. Rus, I. Robles-Fernandez, L. J. Martinez-Gonzalez, R. Carmona, and M. J. Alvarez-Cubero, “Influence of oxidative stress-related genes on susceptibility to fibromyalgia,” Nursing Research, vol. 70, no. 1, pp. 44–50, 2021.
  27. E. Palzur, M. Zaaroor, E. Vlodavsky, F. Milman, and J. F. Soustiel, “Neuroprotective effect of hyperbaric oxygen therapy in brain injury is mediated by preservation of mitochondrial membrane properties,” Brain Research, vol. 1221, pp. 126– 133, 2008.
  28. T. Matsunami, Y. Sato, T. Sato, and M. Yukawa, “Antioxidant status and lipid peroxidation in diabetic rats under hyperbaric oxygen exposure,” Physiological Research, vol. 59, no. 1, pp. 97–104, 2010.
  29. Mense S, Stahnke M. Responses in muscle afferent fibres of slow conduction velocity to contractions and ischaemia in the cat. J Physiol 1983;342(1):383–97
  30. Park JH, Phothimat P, Oates CT, Hernanz-Schulman M, Olsen NJ. Use of P-31 magnetic resonance spectroscopy to detect metabolic abnormalities in muscles of patients with fibromyalgia. Arthritis Rheum 1998;41(3):406–13.
  31. El-Shewy KM, Kunbaz A, Gad MM, et al. Hyperbaric oxygen and aerobic exercise in the long-term treatment of fibromyalgia: A narrative review. Biomed Pharmacother 2019;109:629–38.
  32. Guggino G, Schinocca C, Lo Pizzo M et al.: T helper 1 response is correlated with widespread pain, fatigue, sleeping disorders and the quality of life in patients with fbromyalgia and is modulated by hyperbaric oxygen therapy. Clin Exp Rheumatol 2019; 37 (Suppl. 116): S81-9
  33. A. Hadanny, S. Efrati. The Hyperoxic-Hypoxic Paradox. Biomolecules 2020 Jun 25;10(6):958.
  34. Thom SR. Hyperbaric oxygen: its mechanisms and efficacy. Plast Reconstr Surg. 2011 Jan;127 Suppl 1(Suppl 1):131S-141S
  35. Evaluation of a Hyperbaric Oxygen Therapy Intervention in Individuals with Fibromyalgia.
Curtis K, Katz J, Djaiani C, O’Leary G, Uehling J, Carroll J, Santa Mina D, Clarke H, Gofeld M, Katznelson R.Pain Med. 2021 Jun 4;22(6):1324-1332.
Efrati S, Golan H, Bechor Y, Faran Y, Daphna-Tekoah S, Sekler G, Fishlev G, Ablin JN, Bergan J, Volkov O, Friedman M, Ben-Jacob E, Buskila D. Hyperbaric oxygen therapy can diminish fibromyalgia syndrome–prospective clinical trial. PLoS One. 2015 May 26;10(5):e0127012